Drug Trial Radar · NCT04910776
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
17
Actual
Start
Sep 1, 2021
Primary completion
Mar 2, 2026
Study completion Aug 10, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 days, up to 12 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single group, treatment, Phase 3, open-label study to assess efficacy, safety, pharmacokinetic (PK), pharmacodynamics (PD) of avalglucosidase alfa in treatment-naïve male and female participants with IOPD. Study details include: * Study duration: Screening - up to 4 weeks; * Primary Analysis Period (PAP) - 52 weeks; * Extended Treatment Period (ETP) - 52 weeks; * Extended Long term Treatment Period (ELTP) - 104 weeks; 4-week follow-up period for a total study duration - up to 4.08 years. * Treatment duration: Up to 4 years * Visit frequency: every other week and potentially every week
Conditions
- Glycogen Storage Disease Type II
Interventions
avalglucosidase alfaDrug
Sterile lyophilized powder intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who are alive and free of invasive ventilation at Week 52Time frame: Week 52
Locations
16 sites in 9 countries. Site status is shown where the registry gives one.
Stanford Hospital- Site Number : 8400006
Stanford, California
Children's Hospitals and Clinics of Minnesota- Site Number : 8400008
Minneapolis, Minnesota
Advanced Medical Genetics- Site Number : 8400002
Hawthorne, New York
Duke University Medical Center- Site Number : 8400004
Durham, North Carolina
Cincinnati Children's Hospital Medical Center- Site Number : 8400001
Cincinnati, Ohio
Seattle Children's Hospital- Site Number : 8400003
Seattle, Washington
Investigational Site Number : 0560001
Leuven, Belgium
Investigational Site Number : 1560002
Qingdao, China
Investigational Site Number : 1560001
Shanghai, China
Investigational Site Number : 2760001
Bad Oeynhausen, Germany
Investigational Site Number : 3800002
Monza, Lombardy, Italy
Investigational Site Number : 5280001
Rotterdam, Netherlands
Investigational Site Number : 7240001
Esplugues de Llobregat, Catalunya [Cataluña], Spain
Investigational Site Number : 1580001
Taipei, Taiwan
Investigational Site Number : 8260002
Manchester, United Kingdom
Investigational Site Number : 8260001
London, London, City of, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.